New HIV/AIDS Declaration Seeks To End Inequalities and AIDS by 2030

Red AIDS awareness ribbon on white background

Member states at the just-concluded UN General Assembly High-Level Meeting on AIDS adopted a new HIV/AIDS declaration. They aim to get the world on track to end AIDS as a public health threat by 2030. The member states re-committed to take urgent action in the next five years.

The key HIV/AIDS declaration made at the meeting is to reduce HIV infections to less than 370,000 and annual AIDS-related deaths by 2025. The states also agreed to ending pediatric AIDS and eliminating all forms of HIV-related stigma and discrimination. The vision is to achieve the 95-95-95 testing, treatment, and viral suppression target within all demographics.

The preceding includes children and adolescents living with HIV. Furthermore, by 2025, the states hope to provide access to treatment, medicines, and diagnostics for at least 34 million people living with HIV. Another key declaration is on PrEP (pre-exposure prophylaxis).

The member states commended the progress achieved by several world regions in the fight against HIV/AIDS. They applauded the implementation of the research that resulted in a massive and rapid scaling up of PrEP and the use of post-exposure prophylaxis (PEP). The preceding is in conjunction with treatment as prevention (TasP).

All these treatments led to a rapid reduction in the number of new infections. However, in 2020, despite the COVID-19 pandemic, there were 1.5 million new infections. Despite the latter, PrEP medications continue to help in the effort to curb HIV/AIDS.

As helpful as PrEP drugs are, they are known to have some adverse side effects. The latter is the reason for several lawsuits against Gilead Sciences, the drug manufacturers. If you suffered any of Truvada’s side effects, our mass tort attorneys could help you. Contact us today to find out how.

What Is Pre-Exposure Prophylaxis Treatment?
How Do I Choose the Best Lawyer for My Hernia Mesh Claim?
Medicines You Shouldn’t Take With Proton Pump Inhibitors (PPIs)
Testimonials
Featured FAQs
Free Case Review
Dalimonte Rueb Stoller Logo
Let's Get Started With a Free Case Review